Spots Global Cancer Trial Database for Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Official Title: Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer

Study ID: NCT01472783

Conditions

Recurrent, Epithelial Ovarian Cancer

Interventions

Veliparib

Study Description

Brief Summary: The main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.

Detailed Description: The side effects are modest, since PARP inhibitors affect cancer cells to a much larger extent than normal cells. The effect of this PARP-inhibiting treatment is evident although the greatest effect is seen in patients with mutations in BRCA genes. The reason for this is that BRCA deficient cancer cells are unable to repair both DNA double strand and single strand breaks and undergo apoptosis to a large extent.